AVEKTRUS Trademark

Trademark Overview


On Friday, October 7, 2022, a trademark application was filed for AVEKTRUS with the United States Patent and Trademark Office. The USPTO has given the AVEKTRUS trademark a serial number of 97623312. The federal status of this trademark filing is REGISTERED as of Tuesday, April 30, 2024. This trademark is owned by Kalvista Pharmaceuticals Limited. The AVEKTRUS trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the treatment of angioedema; Pharmaceutical preparations for the treatment of hereditary angioedema; Pharmaceutical preparations for the treatment of bradykinin mediated inflammatory disorders; Pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; Pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders; Pharmaceutical preparations for containing sebetralstat; Pharmaceutical preparations for containing feniralstat(Based on 44(d) Priority Application) Pharmaceutical preparations for the treatment of angioedema; Pharmaceutical preparations for the treatment of hereditary angioedema; Pharmaceutical preparations for the treatment of bradykinin mediated inflammatory disorders; Pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; Pharmaceutical preparations for the treatment of plasma...
avektrus

General Information


Serial Number97623312
Word MarkAVEKTRUS
Filing DateFriday, October 7, 2022
Status700 - REGISTERED
Status DateTuesday, April 30, 2024
Registration Number7370920
Registration DateTuesday, April 30, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, February 13, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations for the treatment of angioedema; Pharmaceutical preparations for the treatment of hereditary angioedema; Pharmaceutical preparations for the treatment of bradykinin mediated inflammatory disorders; Pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; Pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders; Pharmaceutical preparations for containing sebetralstat; Pharmaceutical preparations for containing feniralstat(Based on 44(d) Priority Application) Pharmaceutical preparations for the treatment of angioedema; Pharmaceutical preparations for the treatment of hereditary angioedema; Pharmaceutical preparations for the treatment of bradykinin mediated inflammatory disorders; Pharmaceutical preparations for the treatment of diseases and disorders mediated by the contact activation system; Pharmaceutical preparations for the treatment of plasma kallikrein or factor XIIa mediated diseases or disorders; Pharmaceutical preparations for containing sebetralstat for the treatment of angioedema, hereditary angioedema, bradykinin mediated inflammatory disorders, plasma kallikrein or factor XIIa mediated diseases or disorders, or diseases and disorders mediated by the contact activation system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, October 24, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameKalvista Pharmaceuticals Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressWiltshire SP40BF
GB

Party NameKalvista Pharmaceuticals Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressWiltshire SP40BF
GB

Party NameKalvista Pharmaceuticals Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressWiltshire SP40BF
GB

Trademark Events


Event DateEvent Description
Friday, May 12, 2023NON-FINAL ACTION WRITTEN
Tuesday, October 11, 2022NEW APPLICATION ENTERED
Monday, October 24, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, May 5, 2023ASSIGNED TO EXAMINER
Friday, May 12, 2023NON-FINAL ACTION E-MAILED
Friday, May 12, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, July 31, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, December 26, 2023ASSIGNED TO LIE
Tuesday, December 26, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 26, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, January 11, 2024EXAMINERS AMENDMENT -WRITTEN
Thursday, January 11, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, January 11, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, January 11, 2024EXAMINER'S AMENDMENT ENTERED
Thursday, January 11, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 24, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, February 13, 2024PUBLISHED FOR OPPOSITION
Tuesday, February 13, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 30, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, April 30, 2024REGISTERED-PRINCIPAL REGISTER
Thursday, October 9, 2025ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, October 9, 2025APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, October 9, 2025TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, October 9, 2025TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, October 9, 2025TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, October 9, 2025TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS